This disclosure provides for methods and reagents for rapid multiplex RPA reactions and improved methods for detection of multiplex RPA reaction products. In addition, the disclosure provides new methods for eliminating carryover contamination between RPA processes.

Provided herein is a method for analyzing polynucleotides such as genomic DNA. In certain embodiments, the method comprises: (a) treating chromatin isolated from a population of cells with an insertional enzyme complex to produce tagged fragments of genomic DNA; (b) sequencing a portion of the tagged fragments to produce a plurality of sequence reads; and (c) making an epigenetic map of a region of the genome of the cells by mapping information obtained from the sequence reads to the region. A kit for performing the method is also provided.

Provided herein is a method for analyzing polynucleotides such as genomic DNA. In certain embodiments, the method comprises: (a) treating chromatin isolated from a population of cells with an insertional enzyme complex to produce tagged fragments of genomic DNA; (b) sequencing a portion of the tagged fragments to produce a plurality of sequence reads; and (c) making an epigenetic map of a region of the genome of the cells by mapping information obtained from the sequence reads to the region. A kit for performing the method is also provided.

The invention relates to the field of personalized medicine, and the ability to administer targeted therapies consequently to biomarkers functional identification. In particular, the invention relates to the field of clinical applicable methods for the characterization, and especially the functional evaluation, of genetic variants in a patient. In particular, the invention relates to the field of the characterization, and classification, of variants of uncertain significance (VUS) or other unreported variants in patients. The in vitro method presented here is effective for the characterization of the functional impact of genetic variants in a patient, in particular of VUS, such as BRCA1 and BRCA2 VUS. The inventors have shown that this experimental framework can be used to obtain the necessary biological evidence of VUS function required for the prescription of targeted treatment within three weeks, which is compatible with use in clinical application.

The invention relates to the field of personalized medicine, and the ability to administer targeted therapies consequently to biomarkers functional identification. In particular, the invention relates to the field of clinical applicable methods for the characterization, and especially the functional evaluation, of genetic variants in a patient. In particular, the invention relates to the field of the characterization, and classification, of variants of uncertain significance (VUS) or other unreported variants in patients. The in vitro method presented here is effective for the characterization of the functional impact of genetic variants in a patient, in particular of VUS, such as BRCA1 and BRCA2 VUS. The inventors have shown that this experimental framework can be used to obtain the necessary biological evidence of VUS function required for the prescription of targeted treatment within three weeks, which is compatible with use in clinical application.

The present invention relates to a method of detecting a genetic event, the method comprising steps of partitioning a sample from a subject into a plurality of partitions, and carrying out a digital polymerase chain reaction (dPCR) assay, to determine occurrence of said genetic event.

The present invention relates to a method of detecting a genetic event, the method comprising steps of partitioning a sample from a subject into a plurality of partitions, and carrying out a digital polymerase chain reaction (dPCR) assay, to determine occurrence of said genetic event.

The scChIA-Drop method is a microfluidics-based dual-indexing strategy for single-cell and single-molecule chromatin interaction analysis.

The scChIA-Drop method is a microfluidics-based dual-indexing strategy for single-cell and single-molecule chromatin interaction analysis.

The invention provides a method of determining the epigenetic chromosome interactions which are relevant to a prognostic companion epigenetic test for cancer.